Abeona Therapeutics (ABEO) Common Equity: 2011-2025
Historic Common Equity for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $171.2 million.
- Abeona Therapeutics' Common Equity rose 274.09% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.2 million, marking a year-over-year increase of 274.09%. This contributed to the annual value of $44.0 million for FY2024, which is 196.99% up from last year.
- As of Q3 2025, Abeona Therapeutics' Common Equity stood at $171.2 million, which was up 4.68% from $163.6 million recorded in Q2 2025.
- Abeona Therapeutics' Common Equity's 5-year high stood at $171.2 million during Q3 2025, with a 5-year trough of -$8.9 million in Q1 2024.
- Its 3-year average for Common Equity is $54.1 million, with a median of $41.4 million in 2025.
- Over the last 5 years, Abeona Therapeutics' Common Equity had its largest YoY gain of 683.75% in 2024, and its largest YoY loss of 147.39% in 2024.
- Quarterly analysis of 5 years shows Abeona Therapeutics' Common Equity stood at $42.4 million in 2021, then crashed by 36.84% to $26.8 million in 2022, then crashed by 44.60% to $14.8 million in 2023, then skyrocketed by 196.99% to $44.0 million in 2024, then skyrocketed by 274.09% to $171.2 million in 2025.
- Its Common Equity was $171.2 million in Q3 2025, compared to $163.6 million in Q2 2025 and $41.4 million in Q1 2025.